Blueprint Medicines (BPMC) Misses Q3 EPS by 15c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($1.66), $0.15 worse than the analyst estimate of ($1.51). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $6.86 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy
• NVE Corporation names new CEO and expands board to seven members